Drug test halted in bid to tame rogue immune blood attacks
NCT ID NCT05086744
Summary
This study tested an oral drug called iptacopan in people with two rare autoimmune blood disorders: immune thrombocytopenia (ITP) and cold agglutinin disease (CAD). The goal was to see if the drug could safely help control the diseases by improving patients' platelet or red blood cell counts. The trial was small, ended early, and was not designed to provide final proof of effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Milan, MI, 20122, Italy
-
Novartis Investigative Site
Seoul, 06351, South Korea
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Murcia, 30008, Spain
-
Novartis Investigative Site
London, W12 0HS, United Kingdom
Conditions
Explore the condition pages connected to this study.